Unilateral Hearing Loss in Children: Diagnosis, Aetiology and Management

Unilateral hearing loss (UHL) affects 1-3% of children — 1 in 1000 newborns, rising to 30-40 per 1000 by school age (due to later-onset losses). No sex difference; right and left ears equally affected.

Old paradigm: "One good ear is enough — the child develops normally" — no longer valid. Twenty-five years of literature have proved UHL is a real disability.

Documented impact: Academic — children with UHL repeat grades 2-3 times more often (10-37% reported), require Individualised Education Plans 5x more, increased attention and behaviour problems.

Speech understanding — normal in quiet, but significant difficulty in noise (classroom, cafeteria, playground). Localisation — difficulty finding sound sources (traffic, name calls, play).

Language development — particularly early-onset (congenital) UHL associated with vocabulary, grammar and pragmatic differences. Early intervention (amplification + language support) minimises these gaps.

Social-emotional — fatigue (constant "listening effort with the good ear"), self-esteem, difficulty with peer communication, tendency to isolation. More pronounced in adolescence.

These data require UHL to be treated as "an actionable condition" not "no problem". Modern approach: early diagnosis + individualised amplification + school support. We expand on the clinical framework in our otology and hearing centre.

Congenital UHL: genetic (most commonly Connexin 26 — GJB2 mutation; Connexin 30; mitochondrial), inner ear malformations (enlarged vestibular aqueduct syndrome — EVA; cochlear hypoplasia; Mondini malformation; cochlear nerve hypoplasia/aplasia), congenital CMV (asymptomatic congenital CMV is the leading non-genetic cause of sensorineural loss — up to 25-30% of UHL).

Acquired UHL: viral (mumps — classic unilateral, measles, varicella, herpes), bacterial meningitis (especially children — cochlear labyrinthitis with fibrosis/ossification), trauma (temporal bone fracture, acoustic trauma — fireworks, firearms), Ramsay-Hunt syndrome, ototoxic drugs (chemotherapy, aminoglycosides), noise-induced (late childhood, adolescence — earphone use).

Conductive UHL: chronic otitis media, cholesteatoma, external auditory canal atresia, ossicular discontinuity (trauma), otosclerosis (rare in children).

Diagnostic algorithm: 1) Paediatric audiologic evaluation — age-appropriate pure-tone (play audiometry >3y, VRA 6 mo-3y, ABR in infants), tympanometry, otoacoustic emissions (OAE). 2) Imaging — high-resolution temporal bone CT (bony anatomy, EVA, malformation), inner ear MRI (membranous structures, cochlear nerve, brain parenchyma). MRI is mandatory in CI candidates — nerve absence contraindicates implantation.

3) Genetic testing — GJB2 panel or expanded hearing loss panel (50-200 genes); guided by family history, syndromic features. 4) Congenital CMV — neonatal urine/saliva PCR; later dried blood spot (Guthrie card) testable (3 weeks-3 years meaningful). 5) Other: ophthalmology (electroretinography for Usher), ECG (Jervell-Lange-Nielsen), thyroid (Pendred), urine (Alport).

Mild-moderate sensorineural UHL (PTA 25-55 dB): conventional hearing aid in the poor ear — if residual hearing is sufficient to benefit. Usually adequate for unilateral mild loss.

Moderate-severe sensorineural UHL: CROS (Contralateral Routing of Signal) — microphone on the poor side, signal wirelessly delivered to the good ear; the child partially regains awareness from the poor side. BiCROS — when the good ear also has mild loss (amplification on both).

Bone-conduction devices: BAHA (Bone-Anchored Hearing Aid — osseointegrated post, surgery from age 5; soft band prior) or ADHEAR (adhesive, surgery-free, suitable for younger children). In SSD they transmit poor-side sound through bone to the good cochlea. Similar principle to CROS, different device.

Cochlear implant for single-sided deafness (SSD-CI): major advance of the last decade. Indication: profound/total sensorineural UHL with a good contralateral ear. FDA 2019 approval ≥5y; later extended 9 mo-5y especially in early congenital SSD to minimise auditory deprivation. Outcomes: localisation gain, marked speech-in-noise improvement, social QoL gain. Candidacy: cochlear nerve present (MRI), stable contralateral hearing, language age appropriate.

FM/DM (Remote Microphone) systems: deliver the speaker's (teacher's) voice directly to the child's device/ear in classroom; major SNR advantage (+15-20 dB) over noise. An essential first step for every UHL child in school.

Educational accommodations: seating within 2-3 m of teacher with good ear toward class, reverberation reduction (carpet, curtains, double-glazed), visual supports (text, image), IEP where applicable, SLP support. More detail: hearing loss page.

Newborn hearing screening: OAE/AABR by 1 month, diagnostic evaluation by 3 months, intervention by 6 months ("1-3-6 goals"). Turkey has mandatory nationwide newborn screening through the Ministry of Health.

Because screening is not exhaustive (mild-moderate UHL and late-onset can be missed), children with risk factors (family history, syndrome, NICU stay, hyperbilirubinaemia, prematurity, ototoxic exposure) need periodic surveillance.

CMV screening (universal vs targeted): some countries have begun universal newborn CMV screening (UK 2024, several US states). Early diagnosis enables antiviral therapy (ganciclovir/valganciclovir 6 months) — stabilises hearing in affected infants. In Turkey, targeted (refer) screening.

Paediatric audiologic follow-up: in congenital UHL — 6-monthly to age 3, annual 3-5y, annual through school years. More frequent if EVA (progressive/fluctuating loss with risk of sudden worsening after head trauma).

Speech-language assessment: age-appropriate standardised expressive and receptive language tests, SLP therapy where indicated (typically helpful for most UHL children given language risks).

School entry: education for school counsellor and teacher about UHL, FM/DM evaluation, IEP/504 plan (in Turkey, RAM reports). Annual academic and social integration review.

Adolescent transition: independence support, device acceptance, peer engagement, career counselling (some professions — pilot, military, voice-intensive — may be limited for UHL candidates).

Diagnosis moment: difficult for families; often a long journey from screening "refer" to diagnosis. Honest, comprehensive, non-judgmental communication is important. Written materials + support groups + connection with other families.

Common concerns: "Isn't one ear enough?" — modern evidence: no, intervention helps. "Will the device stigmatise?" — modern minimalist devices; peer acceptance usually not a problem; normalising early is easiest. "What if the good ear is lost?" — particularly in EVA, protecting the good ear is critical (noise, head trauma, pressure change — diving, mountaineering discouraged).

Genetic counselling: GJB2 and other recessive inheritance affects risk for other children; syndromic causes need additional systemic screening; future pregnancies have preimplantation or prenatal options.

CMV (congenital): positive children need multidisciplinary follow-up for systemic complications (eye chorioretinitis, neurodevelopmental, microcephaly, hepatosplenomegaly, thrombocytopenia) — paediatrics, infectious diseases, neurology, ophthalmology. Family education on CMV prevention for future pregnancies.

EVA specifics: progressive loss typical; sudden worsening after head trauma — contact sports limited, helmet use (bike, ski), barotrauma activities (diving, parachuting) discouraged.

SSD adolescence and young adulthood: even if not a CI candidate, may be a CROS/BAHA candidate; listening strategies for noisy social, university and work settings; FM use beneficial in adult settings too.

Inclusion and rights: Turkish regulations may grant 5-40% disability status for hearing loss; education and employment supports in some cases. Families should be informed about rights. Related reading: our patient testimonials.